| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 13F-HR |
| 13 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both programs |
| 05 Nov 2026 | 10-Q |
| 23 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 23, 2026 (the “Effective Date”), Sarepta Therapeutics, Inc. (the “Company”), Sarepta Therapeutics Three, LLC (“Sarepta Three” and, together with the Company, “Sarepta”), REGENXBIO Inc. (“REGENXBIO”), the Trustees of the Univ... |
| 08 Sep 2026 |
Form 4: Wong Ryan Ho-Yan, Chief Financial Officer
Gave up 13,272 shares to cover exercise price or tax ($295K) |
| 08 Sep 2026 |
Form 4: Estepan Ian Michael, Chief Operating Officer
Gave up 24,799 shares to cover exercise price or tax ($551K) |
| 08 Sep 2026 |
Form 4: Rothfuss Cristin, EVP, General Counsel
Gave up 22,025 shares to cover exercise price or tax ($489K) |
| 08 Sep 2026 |
Form 4: Rodino-Klapac Louise, President, R&D and Tech Ops
Gave up 21,423 shares to cover exercise price or tax ($476K) |
| 14 Aug 2026 | 13F-HR |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth |
| 05 Aug 2026 | 10-Q |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 30 Jul 2026 | SCHEDULE 13G/A |
| 29 Jul 2026 |
Form 4: Severino Michael, Director
Received 756,104 shares as a grant or award · Granted 2,224,342 Stock Options (right to buy) |
| 29 Jul 2026 |
Form 3: Severino Michael, Director
No securities owned |
| 28 Jul 2026 | S-8 |
Loading...